Surgical treatment in ovarian cancer prevention in carriers of the BRCA1/BRCA2 mutation;Postȩpowanie chirurgiczne w profilaktyce raka jajnika u nosicielek mutacji genów BRCA1/BRCA2

Ginekologia Polska

Volumn 83, Issue 1, 2012, Pages 51-56

  Synowiec, Agnieszka ^a   Wcisło, Gabriel ^a   Bodnar, Lubomir ^a   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

BRCA1; BRCA2; Ovarian cancer; Prophylaxis bilateral salpingo oophovectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; METHODOLOGY; MIDDLE AGED; OVARIECTOMY; OVARY TUMOR; PRIMARY PREVENTION; REVIEW; RISK FACTOR;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PRIMARY PREVENTION; RISK FACTORS;

EID: 84857126073     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Benedect J, Miller D. Pozostałe nowotwory ginekologiczne. W: Podrȩcznik onkologii klinicznej. Tłumaczenie wydania VII. Red. Pawłe{ogonek}ga J. Kraków: Wyd. Przegla̧d Lekarski. 2001, 519-538.
2. Chora̧ży M. Geny i genetyka-nowe dylematy. Onkologia w praktyce klinicznej. 2005, 1,1-6.
3. Lubiński J, Górski B, Kurzawski G, [i wsp.]. Analizy molekularne w diagnostyce wysokiej genetycznie predyspozycji do nowotworów. Onkol Pol. 2000, 3, 2, 93-97.
4. Grzybowska E, Nowicka E, Lange D, [i wsp.]. Kliniczny przebieg raka piersi u nosicielek germinalnych mutacji w genie BRCA1. Współ Onkol. 2003, 17,742-753.
5. Marshall M, Solomon S. Hereditary breast - ovarian cancer: clinical findings and medical management. Plast Surg Nurs. 2007, 27, 124-127.
6. Carroll J, Cremin C, Allanson J, [et al.]. Hereditary breast and ovarian cancers. Can Fam Physician. 2008, 54,1691-1692.
7. Górski B, Cybulski C, Huzarski T, [et al.]. Breast cancer predisposing allele in Poland. Breast Can Res Treat. 2005, 92, 19-24.
8. Rebbeck T, Kauff N, Domcheck S. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009, 101, 80-87.
9. Tan D, Rothermundt C, Thomas K, [et al.]. "BRCAness" syndrome in ovarian cancer: a casecontrol study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008, 26, 5530-5536.
10. Antoniou A, Pharoah P, Narod S, [et al.]. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet. 2005, 42, 602-603.
11. Ford D, Easton D, Bishop D, [et al.]. Risks of cancer in BRCA-1 mutations carriers. Breast Cancer Linkage Consortium. Lancet. 1994, 343, 692-696.
12. Rebbeck T, Lynch H, Neuhausen S, [et al.]. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Eng J Med. 2002, 346, 1616-1622.
13. Kasprzak L, Foukles W, Shelling A. Hereditary ovarian carcinoma. BMJ. 1999, 318, 786-789.
14. merican Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003, 21, 2397-2406.
15. Robson M, Storm C, Weitzel J, [et al.]. American Society of Clinical Oncology Policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010, 28, 893-901.
16. Balmana J, Diez O, Rubio I, [et al.]. BRCA1 in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2010, 21, 20-22.
17. Lancaster J, Powell C, Kauff N, [et al.]. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007, 107, 159-162.
18. NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: breast and ovarian. v 1.2010; www.nccn.org
19. Domchek S, Rebbeck T. Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol. 2007, 19, 27-30.
20. Eisen A, Lubinski J, Klijn J, [et al.]. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005, 23, 7491-7496.
21. Finch A, Beiner M, Lubinski J, [et al.]. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with BRCA1 or BRCA2 mutation. JAMA. 2006, 296, 185-192.
22. Casey M, Synder C, Bewtra Ch, [et al.]. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol. 2005, 97,457-467.
23. Olivier R, van Beurden M, Lubsen M, [et al.]. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer. 2004, 90, 1492-1497.
24. Metcalfe K, Lynch H, Ghadirian P, [et al.]. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005, 96, 222-226.
25. ACOG Committee on Practice Bulletins. Hereditary breast and ovarian cancer syndrome. Gynecol Oncol. 2009, 113, 6-11.
26. Lynch T, Casey M, Snyder C, [et al.]. Hereditary ovarian carcinoma. Heterogeneity, molecular genetics, pathology, and management. Mol Oncol. 2009, 3, 97-137.
27. Russo A, Calo V, Bruno L, [et al.]. Hereditary ovarian cancer. Crit Rev Oncol Hematol. 2009, 69, 28-44.
28. Rhiem K, Foth D, Wappenschmidt B, [et al.]. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet. 2001, 283, 623-627.
29. Berek J, Chalas E, Edelson M, [et al.]. Prophylactic and risk-reducing bilateral salpingo-oophorectomy. Recommendations based on risk of ovarian cancer. Obstet Gynecol. 2010, 116, 733-744.
30. Carcangiu M, Peissel B, Pasini B, [et al.]. Incidental carcinomas in prophylactic specimes in BRCA1 and BRCA2 germ-line mutations carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol. 2006, 30, 1222-1230.
31. Finch A, Shaw P, Rosen B, [et al.]. Clinical and pathologic findings of prophylactic salpingooophorectomies in 159 BRCA1 and BRCA2 carriers. Genecol Oncol. 2006, 100, 58-64.
32. Lamb J, Garcia R, Goff B, [et al.]. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol. 2006, 194, 1702-1709.
33. Callahan M, Crum C, Medeiros F, [et al.]. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007, 25, 3985-3990.
34. Evans D, Clayton R, Donnai P, [et al.]. Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. Eur J Hum Genet. 2009, 17, 1381-1385.
35. Rabban J, Barnes M, Chen L, [et al.]. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Am J Surg Pathol. 2009, 33, 1125-1136.
36. Domchek S, Friebel T, Garber J, [et al.]. Occult ovarian cancer identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010, 124, 195-203.
37. Haldar K, Crawford R. Risk-reducing salpingo-oophorectomy for BRCA mutation carriers. Maturitas. 2010, 67, 290.
38. Tinelli A, Malvasi A, Leo G, [et al.]. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal. Cancer Metastasis Rev. 2010, 29, 339-350.
39. Kenkhuis M, de Bock G, Elferink P, [et al.]. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers. Maturitas. 2010, 66, 310-314.
40. Willsher P, Ali A, Jackson L. Laparoscopic oophorectomy in the management of breast disease. ANZ J Surg. 2008, 78, 670-672.
41. Gronwald J, Byrski T, Huzarski T. [i wsp.]. Genetyka kliniczna raka piersi i jajnika. W: Genetyka Kliniczna Nowotworów. Red. Lubiński J. Wyd. Hogben. 2009, 59-81.
42. Metcalfe K, Birenbaum-Carmeli D, Lubinski L, [et al.]. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutations carriers. Int J Cancer. 2008, 122, 2017-2022.
43. Menkiszak J, Rzepka-Górska I, Górski B, [et al.]. Attitudes toward preventive oophorectomy among BRCA1 mutation carriers in Poland. Eur J Gynaecol Oncol Oncol. 2004, 25, 93-95.
44. Finch A, Metcalfe K, Lui J, [et al.]. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene. Clin Genet. 2009, 75, 220-224.
45. Satogopan J, Boyd J, Kauff N, [et al.]. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2. Clin Cancer Res. 2002, 8, 3776-3781.
46. Gronwald J, Byrski T, Huzarski T, [et al.]. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat. 2006, 95. 105-109.
47. van der Velde N, Mourits M, Arts H, [et al.]. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer. 2009, 124, 919-923.
48. Domchek S, Friebel T, Neuhausen S, [et al.]. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutations carriers: a prospective cohort study. Lancet Oncol. 2006, 7, 223-229.
49. Rocca W, Grossardt B, de Andrade M, [et al.]. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006, 10, 821-828.
50. Michelsen T, Dørum A, Dahl A. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer. Gynecol Oncol. 2009, 113, 128-133.
51. Astma F, Bartelink M, Grobbee D, van der Schouw Y. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006, 13, 265-279.
52. Lokkegaard E, Jovanovic Z, Heitman B, [et al.]. The association between early menopause and risk of ischaemic heart disease: influense of hormone therapy. Maturitas. 2006, 53, 226-233.
53. Michelsen T, Tonstad S, Pripp A, [et al.]. Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. Int J Gynecol Cancer. 2010, 20, 233-239.
54. Madalinska J, Hollenstein J, Bleiker E, [et al.]. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol. 2005, 23, 6890-6898.
55. van Oostrom I, Meijers-Heijboer H, Lodder L, [et al.]. Long-term impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. J Clin Oncol. 2003, 21, 3867-3874.
56. Riviera C, Grossardt B, Rhodes D, Rocca W. Increased mortality for neurological and mental diseases following early bilateral oophorectomy. Neuroepidemiology. 2009. 33, 32-40.
57. Allain D, Sweet K, Agnese D. Management options after prophylactic surgeries in women with BRCA mutations: a review. Cancer Control. 2007, 14, 330-337.
58. Rebbeck T, Friebel T, Wagner T, [et al.]. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005, 23, 7804-7810.
59. Markowska J. Profilaktyczne usuniȩcie gonad u kobiet nosicielek mutacji w genach BRCA. W: Ginekologia onkologiczna. Red. Markowska J. Tom 2. Wrocław: Wyd. Medyczne Urban & Partner. 2006, 945-948.